Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Other Non-Current Liabilities (2021 - 2025)

Xeris Biopharma Holdings' Other Non-Current Liabilities history spans 5 years, with the latest figure at $8.4 million for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Liabilities rose 326.94% year-over-year to $8.4 million, compared with a TTM value of $8.4 million through Dec 2025, up 326.94%, and an annual FY2025 reading of $8.4 million, up 326.94% over the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $8.4 million at Xeris Biopharma Holdings, up from $3.4 million in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $30.2 million in Q2 2022, with the low at $31000.0 in Q1 2023.
  • Average Other Non-Current Liabilities over 5 years is $10.5 million, with a median of $5.6 million recorded in 2023.
  • Year-over-year, Other Non-Current Liabilities tumbled 99.88% in 2023 and then surged 19461.29% in 2024.
  • Tracing XERS's Other Non-Current Liabilities over 5 years: stood at $22.5 million in 2021, then grew by 14.01% to $25.7 million in 2022, then plummeted by 81.13% to $4.8 million in 2023, then plummeted by 59.43% to $2.0 million in 2024, then skyrocketed by 326.94% to $8.4 million in 2025.
  • Per Business Quant, the three most recent readings for XERS's Other Non-Current Liabilities are $8.4 million (Q4 2025), $3.4 million (Q3 2025), and $7.8 million (Q2 2025).